Abstract
From January 1988 to October 1992, the primary resistance to first-line antituberculous drugs in 501 tuberculous patients was evaluated prospectively. Three-hundred and seventeen patients were HIV-negative and 184 were HIV-positive; these patients had several different clinical forms of tuberculosis. Moreover, the acquired resistance to antituberculous drugs was studied in 295 non-AIDS patients and in 42 AIDS patients with evidence of antecedent tuberculosis treatment. The data indicated that during these five years there was no consistent and clear-cut trend toward greater frequency of primary drug resistance to any of the first-line antituberculous drugs. Primary drug resistance in HIV-positive patients (7.1 %) did not differ significantly (p>0.05) from that found in HIV-negative patients (8.2 %). Among HIV-positive patients, the acquired drug resistance pattern was similar to that detected in HIV-negative patients although the frequency of resistance in the former (69 %) was significantly higher (p<0.01). During the study, resistance to isoniazid was almost constant in the acquired-resistance cases and was frequently associated with resistance to other drugs. Furthermore, the acquired resistance to isoniazid was often of a higher level (1 to 10 mg/l) than the primary resistance (0.2 mg/l), and those strains were usually catalase and peroxidase negative.
Similar content being viewed by others
References
Centers for Disease Control: National action plan to combat multidrug-resistant tuberculosis. Morbidity and Mortality Weekly Report 1992, 41: 5–47.
Bloch AB, Cauthen GM, Onorato IM, Dansbury KG, Kelly GD, Driver CR, Snider DE: Nationwide survey of drug-resistant tuberculosis in the United States. Journal of the American Medical Association 1994, 271: 665–671.
Chawla PK, Klapper PJ, Kamholz SL, Pollack AH, Henrich AE: Drug-resistant tuberculosis in an urban population including patients at risk for human immunodeficiency virus infection. American Review of Respiratory Disease 1992, 146: 280–284.
Beck-Sagué C, Dooley SW, Hulton MD, Otten J, Breeden A, Crawford JT, Pitchenik AE, Woodley CH, Cauthen G, Jarwis WR: Hospital outbreak of multidrug-resistantMycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. Journal of the American Medical Association 1992, 268: 1280–1286.
Busillo Ch P, Lessnau KD, Sanjana V, Soumakis S, Davidson M, Muller MP, Talavera W: Multidrug resistantMycobacterium tuberculosis in patients with human immunodeficiency virus infection. Chest 1992, 102: 797–801.
Edlin BR, Tokars JI, Griego MH, Crawford JT, Williams JN, Sordillo ME, Ong KR, Kilburn JO, Dooley SW, Castro KG, Jarvis WR, Holmberg SD: An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. The New England Journal of Medicine 1992, 326: 1514–1521.
Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, Jarvis WR: Nosocomial transmission of multidrug-resistantMycobacterium tuberculosis. At risk patients and health care workers. Annals of Internal Medicine 1992, 117: 191–196.
Fischl MA, Daikos GL, Uttamchandani RB, Poblete RB, Moreno JN, Reyes RR, Boota AM, Thompson LM, Cleary TJ, Oldham SA, Saldana MJ, Lai S: Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multidrug-resistant bacilli. Annals of Internal Medicine 1992, 117: 184–190.
Bloom BR, Murray CJL: Tuberculosis: commentary on a reemergent killer. Science 1992, 257: 1055–1064.
Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW: The emergence of drug-resistant tuberculosis in New York City. The New England Journal of Medicine 1993, 328: 521–526.
Centers for Disease Control: Transmission of multidrug-resistant tuberculosis from an HIV-positive client in a residential substance-abuse treatment facility. Morbidity and Mortality Weekly Report 1991, 40: 129–131.
Dooley SW, Jarvis WR, Martone WJ, Snider DE: Multidrug-resistant tuberculosis. Annals of Internal Medicine 1992, 117: 257–259.
Hinman AR, Hughes JM, Snider DE, Cohen ML: Meeting the challenge of multidrug-resistant tuberculosis: summary of a conference. Morbidity and Mortality Weekly Report 1992, 41: 49–57.
Centers for Disease Control: Probable transmission of multidrug-resistant tuberculosis in a correctional facility. Morbidity and Mortality Weekly Report 1993, 42: 48–51.
Ausina V, Matas L, Mirelis B, Coll P, Castella J, Prats G: Estudio de las resistencias bacterianas primarias en enfermos tuberculosos en un hospital general. Medicina Clinica 1984, 82: 741–744.
Ausina V, Garcia-Barceló M, Luquín M, Belda F, Fernadez J, Esteban G, Sauret J, Mirelis B, Prats G: Estudio de las resistencias bacterianas primarias e iniciales en enfermos tuberculosos de un hospital general durante 1983–1987. Enfermedades Infecciosas y Microbiología Clínica 1990, 8: 274–277.
Canetti G, Grosset G: Techniques et indications des exames bacteriologiques en tuberculosis. Paris. Editions de la Tourelle 1976, p. 77–115.
Heifets LB: Rapid automated method (Bactec system) in clinical mycobacteriology. Seminars in Respiratory Infections 1986, 1: 242–249.
Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond ED, Sierra MF, Schoolnik GK: Exogenous reinfection with multidrug-resistantMycobacterium tuberculosis in patients with advanced HIV-infection. The New England Journal of Medicine 1993, 328: 1137–1144.
Canetti G, Lelirzin M, Gay P, Thibier R, Kreis B, Grosset J: La résistance primaire dans la tuberculose pulmonaire de l'adult en France (1966–1970). Review de Tuberculose et Pneumologie 1972, 36: 337–356.
Schweiger O, Vandra E: The bacteriologic and clinical significance of the catalase activity ofMycobacterium tuberculosis. American Review Tuberculosis 1958, 78: 735–748.
Jackett PS, Aber VR, Lowrie DB: Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains ofMycobacterium tuberculosis. Journal General Microbiology 1978, 104: 37–45.
Cohn ML, Kovitz C, Oda U, Middlebrook G: Studies on isoniazid and tubercle bacilli. II: The growth requeriments, catalase activities, and pathogenic properties of isoniazid-resistant mutants. American Review Tuberculosis 1954, 70: 641–664.
Oestraicher R, Dressler SH, Russell WF, Grow JB, Middlebrook G: Observations on the pathogenicity of isoniazid-resistant mutants of tubercle bacilli for tuberculosis patients. American Review Tuberculosis 1955, 71: 390–405.
Middlebrook G, Cohn ML: Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953, 118: 297–299.
Snider DE, Kelly GD, Ganther GM, Thompson NJ, Killburn JO: Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. American Review of Respiratory Disease 1985, 132: 125–132.
Zhang Y: Genetic basis of isoniazid resistance ofMycobacterium tuberculosis. Research Microbiology 1993, 144: 143–149.
Zhang Y, Heym B, Allen B, Young D, Cole S: The catalase-peroxidase gene and isoniazid resistance ofMycobacterium tuberculosis. Nature 1992, 358: 591–593.
Stoeckle MY, Gruan L, Riegler L, Weitzman I, Kreiswirth B, Kornblum J, Laraque F, Riley LW: Catalase-peroxidase gene sequences in isoniazid-sensitive and isoniazid-resistant strains ofMycobacterium tuberculosis from New York city. Journal of Infectious Diseases 1993, 168: 1063–1065.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ausina, V., Riutort, N., Viñado, B. et al. Prospective study of drug-resistant tuberculosis in a spanish urban population including patients at risk for HIV infection. Eur. J. Clin. Microbiol. Infect. Dis. 14, 105–110 (1995). https://doi.org/10.1007/BF02111867
Issue Date:
DOI: https://doi.org/10.1007/BF02111867